Archive: Brixadi

People receiving care for severe opioid use disorder (OUD) are at increased risk of relapse. This makes it critical to manage opioid overdose in a timely manner. Naloxone is a cornerstone in the emergency treatment of known or suspected overdose and it can be added as an extra safety measure to prevent serious harm or death. ... Read more

Brixadi is the brand name for a buprenorphine extended-release injection. It was first approved by the United States Food and Drug Administration in May 2023. Like other drugs that contain buprenorphine, Brixadi is used in treating moderate to severe opioid use disorder (OUD). However, unlike oral forms of buprenorphine, Brixadi has to be administered by ... Read more

Brixadi was approved by the FDA (U.S. Food and Drug Administration) on May 23, 2023, after about five years of clinical trials and formal applications to the FDA.   Before any drug can be approved, it undergoes a meticulously designed process to weigh its potential benefits against its risks. The FDA then decides if it’s safe ... Read more

Brixadi is the brand name of an injectable drug that contains buprenorphine and is used to treat opioid use disorder (OUD). Suboxone is the brand name of an orally-administered drug that contains a combination of buprenorphine and naloxone. When treating OUD, a doctor will prescribe Brixadi at the beginning. It needs close monitoring, so this part ... Read more

Brixadi is a brand name for a slow-release, injectable medication made subcutaneously (under the skin). It contains buprenorphine, which received FDA approval on May 23, 2023, to treat moderate to severe opioid dependence. This article breaks down everything you need to know about the Brixadi injection. What Are the Available Brixadi’s Dosage Forms and Strengths? ... Read more

People have long expressed their concerns for compliance on the daily sublingual buprenorphine formulations. Then along came Brixadi, which uses the same active ingredient in weekly and monthly injection options, making it easier than ever to not miss a dose. Before switching from daily sublingual buprenorphine to Brixadi, many people wonder how affordable it is. The ... Read more

Buprenorphine and its derivatives have had a decades-long history of successfully helping in the treatment of opioid withdrawal syndrome. Still, every now and then we get to see an improvement to the familiar formula with the potential to be a gamechanger in addiction treatment. Brixadi, a newly approved buprenorphine-based intravenous injection is notable for being ... Read more

One of the most recent opioid addiction drugs to pass clinical trials and hit the market is Brixadi, an injectable form of extended-release buprenorphine for treating moderate to severe opioid addiction. Let’s examine how Brixadi performed during clinical trials and how effective it is for treating opioid use disorder, as well as how it fares ... Read more

Access to effective addiction treatment can sometimes be hindered by financial constraints This is where the Brixadi Copay Assistance Program comes into play. It’s designed to make the addiction medication Brixadi more affordable and accessible to individuals struggling with opioid use disorder. Read on to learn how Brixadi Copay Assistance works and how you can ... Read more